Normal Human Serum - Complement (1.0 mL)

Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50.


Product Specifications

Citations 35
Description

Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50.

Storage Store at or below –70˚C
Form

Frozen Liquid

Concentration N/A
Applications

See citations and technical data sheet for application info.

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.
Catalog Number A111
Catalog Number (CE) N/A
Size 1.0 mL
Price (USD) $80.00
Price (EURO) 70,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50.

Size 1.0 mL
Storage

Store at or below –70˚C

Form Frozen Liquid
Concentration N/A
Applications See citations and technical data sheet for application info.
Purity N/A
Source

Human blood

Activity N/A
Molecular Weight N/A
Background

Because the anticoagulants used in the preparation of plasma (EDTA, ACD and even heparin) can interfere with complement activation in vitro, serum has long been used as a human complement source for experimentation. Many commercially available sera, however, are not processed appropriately to conserve complement activity. Lyophilization and plasma recalcification can raise background levels of complement split products (SC5b-9 or TCC, iC3b, Bb, C4d and particularly the anaphylatoxins C3a, C5a and C4a) and decrease CH50. Sera, however, must be processed quickly and correctly to prevent complement turnover. For this reason, sera obtained from blood banks and other large pools may not be suitable for many experimental procedures. Conversely, in house serum draws are complicated by several factors including the necessity of maintaining standardized pools of complement for ongoing experimentation and the confidentiality requirements relating to infectious disease testing. QuidelOrtho Normal Human Serum Complement is designed to address these specific issues.

Citations

Title Year Applications Sample Species Sample Sample Details

The Vi capsular polysaccharide enables Salmonella enterica serovar typhi to evade microbe-guided neutrophil chemotaxis.

2014

ELISA

Bacteria

Salmonella enterica

Antigenic Variation in Streptococcus pneumoniae PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity.

2018

FC

Bacteria

Streptococcus pneumoniae

Loss of very-long O-antigen chains optimizes capsule-mediated immune evasion by Salmonella enterica serovar Typhi.

2013

FC

Bacteria

Salmonella enterica

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

2008

CDC Assay

Cell Culture

Daudi Cells

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

2008

CDC Assay

Cell Culture

Ramos Cells

Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity

2011

CDC Assay

Cell Culture

sLea antigen

positive and negative cell lines

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others

2013

CDC Assay

Cell Culture

RC-K8 cells

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others

2013

CDC Assay

Cell Culture

SU-DHL-4 cells

Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles

2013

CDC Assay

Cell Culture

Huh7.5 Cells

The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP80

2013

CDC Assay

Cell Culture

OPM-2 cells

Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.

2013

CDC Assay

Cell Culture

MDA-MB-231 Cells

Real time assays for quantifying cytotoxicity with single cell resolution.

2013

CDC Assay

Cell Culture

Jeko-1 Cells

Lymphoma cells

Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.

2014

CDC Assay

Cell Culture

Daudi Cells

Comparability of a three-dimensional structure in biopharmaceuticals using spectroscopic methods.

2014

CDC Assay

Cell Culture

WIL2-S cells

A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus.

2015

CDC Assay

Cell Culture

CHO Cells

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.

2016

CDC Assay

Cell Culture

KIT225/K6 cells

T0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFα.

2017

CDC Assay

Cell Culture

CHO cells

Recruitment of Factor H to the Streptococcus suis Cell Surface is Multifactorial.

2016

Phagocytosis assay

Cell Culture

THP-1 Cells

Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement

2012

TER Measurements

Cell Culture

RPE Cells

Engineered antibody Fc variants with enhanced effector function

2006

CDC Assay

Human

WIL2-S cells

Rituximab

Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys

2011

CDC Assay

Human

B-Cells

Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.

2011

CDC Assay

Human

Peripheral blood mononuclear cells

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

2012

CDC Assay

Human

WIL2-S cells

CD-20 AbX antibody

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

2012

CDC Assay

Human

Peripheral blood mononuclear cells

A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.

2017

CDC Assay

Human

A549 cells

A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.

2017

CDC Assay

Human

WIL2-S cells

Interleukin-1β and cathepsin D modulate formation of the terminal complement complex in cultured human disc tissue.

2021

Complement Activation Assay

Human

Disc Tissue

Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product.

2021

ELISA

Human

Serum

Bioactive lysophospholipids generated by hepatic lipase degradation of lipoproteins lead to complement activation via the classical pathway

2014

ELISA

Human

Serum

Complement c5a generation by staphylococcal biofilms

2013

FC

Human

Serum

Staphylococcus epidermidis incubated

Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs.

2017

FC

Human

Peripheral blood mononuclear cells

Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction

2013

Mass Spec

Human

Red Blood Cells

Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury

2009

TER Measurements

Human

ARPE-19 Cells

Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells.

2015

ELISA

Virus

HIV

Purified

Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes

2012

VCA

Virus

HIV

Purified